Abstract

COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a pandemic disease and is the major cause of deaths worldwide. The clinical complexities (inflammation, cytokine storm, and multi-organ dysfunction) associated with COVID-19 poses constraints to effective management of critically ill COVID-19 patients. Low dose radiation therapy (LDRT) has been evaluated as a potential therapeutic modality for COVID-19 pneumonia. However, due to heterogeneity in disease manifestation and inter-individual variations, effective planning for LDRT is limited for this large-scale event. 2-deoxy-D-glucose (2-DG) has emerged as a polypharmacological agent for COVID-19 treatment due to its effects on the glycolytic pathway, anti-inflammatory action, and interaction with viral proteins. We suggest that 2-DG will be a potential adjuvant to enhance the efficacy of LDRT in the treatment of COVID-19 pneumonia. Withal, azido analog of 2-DG, 2-azido-2-DG can produce rapid catastrophic oxidative stress and quell the cytokine storm in critically ill COVID-19 patients.

摘要

由严重急性呼吸系统综合症冠状病毒2（SARS-CoV-2）引起的COVID-19是一种大流行病，是全球范围内死亡的主要原因。与COVID-19相关的临床复杂性（炎症，细胞因子风暴和多器官功能障碍）对重症COVID-19患者的有效治疗提出了限制。低剂量放射治疗（LDRT）已被评估为COVID-19肺炎的潜在治疗方式。但是，由于疾病表现的异质性和个体之间的差异，对于此大规模事件而言，LDRT的有效计划受到限制。由于2-脱氧-D-葡萄糖（2-DG）对糖酵解途径，抗炎作用以及与病毒蛋白的相互作用，因此已成为用于COVID-19治疗的多药治疗剂。我们建议2-DG将成为潜在的佐剂，以增强LDRT在治疗COVID-19肺炎中的疗效。2-DG，2-叠氮基-2-DG的Withal，叠氮基类似物可在重症COVID-19患者中产生快速的灾难性氧化应激，并平息细胞因子风暴。